DOUBLE BOND PHARMACEUTICAL
Double Bond Pharmaceutical company which develops and commercialises innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases and other life-threatening disorders. The main aim of the company is to provide patients and the market with more efficient and safe products in areas where these needs are unmet.
DOUBLE BOND PHARMACEUTICAL
Industry:
Biotechnology Pharmaceutical
Founded:
2014-01-01
Address:
Uppsala, Uppsala Lan, Sweden
Country:
Sweden
Website Url:
http://www.doublebp.com
Total Employee:
1+
Status:
Active
Contact:
+4673-5700203
Email Addresses:
[email protected]
Total Funding:
71.43 K EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx Sitelinks Search Box
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Double Bond Pharmaceutical
Official Site Inspections
http://www.doublebp.com
- Host name: webfront4.webcluster.loopia.se
- IP address: 93.188.2.54
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Double Bond Pharmaceutical"
Double Bond Pharmaceutical - Crunchbase Company Profile
Contact Email [email protected] Phone Number +4673-5700203 Double Bond Pharmaceutical company which develops and commercialises innovative first-in-class approaches for โฆSee details»
Q3 2024 - Double Bond Pharmaceutical
Nov 14, 2024 Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082. Stock short name: DBP BSee details»
Double Bond Pharmaceutical International AB | LinkedIn
Double Bond Pharmaceutical International AB | 1 289 följare på LinkedIn. Double Bond Pharmaceutical is a fast growing pharmaceutical company that develops and commercializes โฆSee details»
DBP International and Vivo Biopharma Enter into Asset Purchase โฆ
Sep 17, 2023 Sauvie Inc. is a private biopharma organization and currently advancing a novel immuno-oncology technology, a bispecific camelid nanobody platform for multiple cancer โฆSee details»
Double Bond Pharmaceutical - Contacts, Employees, Board โฆ
Double Bond Pharmaceutical company which develops and commercialises innovative first-in-class approaches for treatment of cancers.See details»
Double Bond Pharmaceuticals - Products, Competitors, Financials ...
Doublebp.com. Overview & Products; People; About Double Bond Pharmaceuticals. Double Bond Pharmaceuticals is a pharmaceutical company that focuses on the development and โฆSee details»
Double Bond Pharmaceutical International AB: DBP International โฆ
Jun 12, 2020 The meeting granted discharge to the Board members and the CEO for the past year. directors: The following persons were re-elected as ordinary members: Per Stalhandske โฆSee details»
Double Bond Pharmaceutical International AB (Double Bond โฆ
ไบ่งฃDouble Bond Pharmaceutical International AB (Double Bond Pharmaceutical International AB)ๅ ฌๅธ็่ฏ็ฉ็ฎก็บฟ๏ผๆฒป็้ขๅ๏ผๆๆฏๅนณๅฐ๏ผไปฅๅๅฎ็1้กนไธดๅบ่ฏ๏ผ็พ็ ้ขๅ:่ฟ็ค๏ผ็ฅ็ป็ณป็ป โฆSee details»
Fullmakt - Double Bond Pharmaceutical
Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082. Stock short name: DBP BSee details»
Double Bond Pharmaceutical International - Simply Wall St
Dec 1, 2024 www.doublebp.com: Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches โฆSee details»
DBP International AB: Named Patient Early Access Program with ...
Nov 23, 2021 E-mail: [email protected]. Follow us on LinkedIn and Twitter! _____ Information about Double Bond Pharmaceutical International AB. DBP is a pharmaceutical company with โฆSee details»
Supplement to Press Release: DBP International AB and Vivo โฆ
Sep 19, 2023 The press release is supplemented with the paragraph "Further details of the agreements" Double Bond Pharmaceutical International AB (publ) (โDBPโ) and Vivo โฆSee details»
Q3 rapport 2022 โ Double Bond Pharmaceutical
[fusion_builder_container admin_label="" hundred_percent="no" equal_height_columns="no" menu_anchor="" hide_on_mobile="small-visibility,medium-visibility,large ...See details»
Zoono : DBP International AB, Zoono's products will be available at ...
Oct 29, 2020 After replenishing its stock, Double Bond Pharmaceuticals subsidiary Drugsson AB has now received an order from Apotek365. The products will soon be sold at online โฆSee details»
Q3 2024 - doublebp.com
2 FINANSIELL ÖVERSIKT TREDJE KVARTALET 2024-07-01 โ 2024-09-30 Totala intäkter uppgick till 0,2 (0,3) MSEK Rörelseresultatet uppgick till -1,7 (-2,3) MSEKSee details»
DBP International AB: Joint Venture agreement with Shijiazhuang โฆ
May 21, 2020 E-mail: [email protected]. Follow us on LinkedIn and Twitter! _____ Information on Double Bond Pharmaceutical International AB. DBP is a pharmaceutical company with the โฆSee details»
DBP International AB and Vivo Biopharma LLC Enter into Asset โฆ
Sep 17, 2023 Double Bond Pharmaceutical International AB (publ) (โDBPโ) and Vivo Biopharma LLC (โVivoโ), a wholly owned subsidiary of Sauvie Inc. (โSauvieโ) today announced that they โฆSee details»
Q3 rapport 2021 - Double Bond Pharmaceutical
Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082. Stock short name: DBP BSee details»
Press Releases - Double Bond Pharmaceutical
All press releases about our company Double Bond Pharmaceutical are published by Spotlight Stock Market on their website.See details»
DBP International: The clinical protocol for the SI-053 phase I trial ...
May 12, 2021 Preparation of the trial protocol was accomplished in close collaboration with Investigators as well as contract research organization, CATO SMS. "The completion of the โฆSee details»